| 1. |
- Thompson, Paul M., et al.
(författare)
-
The ENIGMA Consortium : large-scale collaborative analyses of neuroimaging and genetic data
- 2014
-
Ingår i: BRAIN IMAGING BEHAV. - : Springer Science and Business Media LLC. - 1931-7557 .- 1931-7565. ; 8:2, s. 153-182
-
Tidskriftsartikel (refereegranskat)abstract
- The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA's first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
|
|
| 2. |
- De Caterina, Raffaele, et al.
(författare)
-
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes : ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Position Paper
- 2012
-
Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 0735-1097 .- 1558-3597. ; 59:16, s. 1413-1425
-
Forskningsöversikt (refereegranskat)abstract
- Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral anticoagulants targeting the single coagulation enzymes thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, and edoxaban) and given in fixed doses without coagulation monitoring. Here we review the pharmacology and the results of clinical trials with these new agents in stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, providing perspectives on their future incorporation into clinical practice. In phase III trials in atrial fibrillation, compared with warfarin, dabigatran etexilate 150 mg B.I.D. reduced the rates of stroke/systemic embolism without any difference in major bleeding; dabigatran etexilate 110 mg B.I.D. had similar efficacy with decreased bleeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism, and mortality as well as major bleeding; and rivaroxaban 20 mg Q.D. was noninferior to warfarin for stroke and systemic embolism without a difference in major bleeding. All these agents reduced intracranial hemorrhage. Edoxaban is currently being evaluated in a further large phase III trial. Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischemia in patients with acute coronary syndromes who were mostly receiving dual antiplatelet therapy, with conflicting results on efficacy but consistent results for increased major bleeding. Overall, the new oral anticoagulants are poised to replace vitamin K antagonists for many patients with atrial fibrillation and may have a role after acute coronary syndromes. Although convenient to administer and manage, they present challenges that need to be addressed.
|
|
| 3. |
- De Caterina, Raffaele, et al.
(författare)
-
Parenteral anticoagulants in heart disease : Current status and perspectives (Section II) Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
- 2013
-
Ingår i: Thrombosis and Haemostasis. - 0340-6245 .- 2567-689X. ; 109:5, s. 769-786
-
Tidskriftsartikel (refereegranskat)abstract
- Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.
|
|
| 4. |
- De Caterina, Raffaele, et al.
(författare)
-
Vitamin K antagonists in heart disease : Current status and perspectives (Section III)
- 2013
-
Ingår i: Thrombosis and Haemostasis. - 0340-6245 .- 2567-689X. ; 110:6, s. 1087-1107
-
Tidskriftsartikel (refereegranskat)abstract
- Oral anticoagulants are a mainstay of cardiovascular therapy, and for over 60 years vitamin K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere with the cyclic inter-conversion of vitamin K and its 2,3 epoxide, thus inhibiting gamma-carboxylation of glutamate residues at the amino-termini of vitamin K-dependent proteins, including the coagulation factors (F) II (prothrombin), VII, IX and X, as well as of the anticoagulant proteins C, S and Z. The overall effect of such interference is a dose-dependent anticoagulant effect, which has been therapeutically exploited in heart disease since the early 1950s. In this position paper, we review the mechanisms of action, pharmacological properties and side effects of VKAs, which are used in the management of cardiovascular diseases, including coronary heart disease (where their use is limited), stroke prevention in atrial fibrillation, heart valves and/or chronic heart failure. Using an evidence-based approach, we describe the results of completed clinical trials, highlight areas of uncertainty, and recommend therapeutic options for specific disorders. Although VKAs are being increasingly replaced in most patients with non-valvular atrial fibrillation by the new oral anticoagulants, which target either thrombin or FXa, the VKAs remain the agents of choice for patients with atrial fibrillation in the setting of rheumatic valvular disease and for those with mechanical heart valves.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Svensson, Tommy, 1970, et al.
(författare)
-
CELTIC CP5-026 WINNER+, D1.9 Final Innovation Report
- 2010
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This deliverable is the final innovation report from the innovation workpackage in WINNER+. The document describes the latest innovations and their assessment as well as summarizes the innovations developed in the work package during the project. We analyze the suitability of these innovations as technology enablers for improving current systems, in particular IMT Advanced and beyond.
|
|
| 8. |
- Ahlborg, Liv, et al.
(författare)
-
Non-technical factors influence laparoscopic simulator performance among OBGYN residents
- 2012
-
Ingår i: Gynecological Surgery. - : Springer. - 1613-2076 .- 1613-2084. ; 9:4, s. 415-420
-
Tidskriftsartikel (refereegranskat)abstract
- In addition to technical skills, nontechnical factors appear to influence surgical results. This study aims to analyze how visuospatial ability, self-efficacy, and flow are associated with simulated laparoscopic performance of residents in obstetrics and gynecology (OBGYN). In this cohort study, 28 residents in obstetrics and gynecology were tested for visuospatial ability and self-efficacy prior to simulator training. All participants subsequently conducted a basic set of tasks in the simulator. Self-efficacy, once again, and flow were assessed after training. Nineteen of the subjects then completed a 2-day course with identical simulator tasks, although now to a predefined credential level. Visuospatial ability correlated with simulator performance in the technically most advanced simulator task in the basic set ("total time," r=-0.40, p=0.039). Flow correlated with: "right instrument pathway"(r=-0.40, p=0.004) in that same task and with the 2-day overall training results (r=-0.56, p=0.017). Self-efficacy correlated with the 2-day result (r=-0.56, p=0.013) and significantly improved after training (p=0.011). When constructing a curriculum for OBGYN residents, visuospatial abilities and non-technical factors like flow and self-efficacy should be considered.
|
|
| 9. |
- Azmi, Marwan H., et al.
(författare)
-
Design of Multi-Edge-Type Bilayer-Expurgated LDPC Codes for Decode-and-Forward in Relay Channels
- 2011
-
Ingår i: IEEE Transactions on Communications. - 0090-6778 .- 1558-0857. ; 59:11, s. 2993-3006
-
Tidskriftsartikel (refereegranskat)abstract
- We consider the design of bilayer-expurgated low-density parity-check (BE-LDPC) codes as part of a decode-and-forward protocol for use over the full-duplex relay channel. A new ensemble of codes, termed multi-edge-type bilayer-expurgated LDPC (MET-BE-LDPC) codes, is introduced where the BE-LDPC code design problem is transformed into the problem of optimizing the multinomials of a multi-edge-type LDPC code. We propose two design strategies for optimizing MET-BE-LDPC codes; the bilayer approach is preferred when the difference in SNR between the source-to-relay and the source-to-destination channels is small, while the bilayer approach with intermediate rates is preferred when this difference is large. In both proposed design strategies multi-edge-type density evolution is used for code optimization. The resulting MET-BE-LDPC codes exhibit improved threshold and bit-error-rate performance as compared to previously reported bilayer LDPC codes.
|
|
| 10. |
- Bertz, Fredrik, et al.
(författare)
-
Diet and exercise weight-loss trial in lactating overweight and obese women
- 2012
-
Ingår i: American Journal of Clinical Nutrition. - : Elsevier BV. - 0002-9165. ; 96:4, s. 698-705
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Current evidence suggests a combined treatment of postpartum weight loss of diet and exercise. However, to our knowledge, neither their separate and interactive effects nor long-term outcomes have been evaluated. Objective: We evaluated whether a 12-wk dietary behavior modification (D) treatment to decrease energy intake, physical exercise behavior modification (E) treatment to implement moderate aerobic exercise, or combined dietary and physical exercise behavior modification (DE) treatment compared with control (usual care) (C) reduces body weight in lactating women measured at the end of treatment and at a 1-y follow-up 9 mo after treatment termination. Design: At 10-14 wk postpartum, 68 lactating Swedish women with a prepregnancy BMI (in kg/m(2)) of 25-35 were randomly assigned to D, E, DE, or C groups. Measurements were made at baseline, after the intervention, and again at a 1-y follow-up 9 mo later. A 2 x 2 factorial approach was used to analyze main and interaction effects of treatments. Results: Weight changes after the intervention and 1-y follow-up were -8.3 +/- 4.2 and -10.2 +/- 5.7 kg, respectively, in the D group; -2.4 +/- 3.2 and -2.7 +/- 5.9 kg, respectively, in the E group; -6.9 +/- 3.0 and -7.3 +/- 6.3 kg, respectively, in the DE group; and -0.8 +/- 3.0 and -0.9 +/- 6.6 kg, respectively, in the C group. The main effects of D treatment, but not of E treatment, on weight were significant at both times (P < 0.001). Conclusions: Dietary treatment provided clinically relevant weight loss in lactating postpartum women, which was sustained at 9 mo after treatment. The combined treatment did not yield significant weight or body-composition changes beyond those of dietary treatment alone. This trial was registered at clinicaltrials.gov as NCT01343238. Am J Clin Nutr 2012;96:698-705.
|
|
